EVERSANA has added another feature to its ORCHESTRATE platform for the commercialisation of life science products – an artificial intelligence-powered toolkit designed to make medical, legal, and regulatory (MLR) review processes more accurate and efficient.

EVERSANA在其用于生命科学产品商业化的ORCHESTRATE平台中新增了一项功能——一个由人工智能驱动的工具包，旨在使医学、法律和监管（MLR）审查流程更加准确和高效。

The newly launched EVERSANA ORCHESTRATE MLR can automate 90% of the common tasks in MLR, a complex and often time-consuming and costly review process that companies carry out to make sure their advertising and promotional content is accurate, compliant with regulations, and okay to be published.

新推出的EVERSANA ORCHESTRATE MLR可以自动完成MLR中90%的常见任务。MLR是一个复杂且通常耗时且昂贵的审查过程，公司通过该流程确保其广告和宣传内容准确无误、符合法规并可以发布。

It is a critical task to make sure that the content is 100% accurate – otherwise, patient safety could be compromised and companies could be exposed to the risk of hefty fines, litigation risks, and damage to their reputations.

确保内容 100% 准确是一项关键任务——否则，患者安全可能会受到威胁，公司也可能面临巨额罚款、诉讼风险以及声誉受损的风险。

With its new launch,

随着它的新推出，

EVERSANA

EVERSANA

aims to streamline the MLR process, which remains a largely manual effort in most organisations, generally takes weeks to complete, and according to some estimates can cost large companies tens of millions of dollars per year.

旨在简化 MLR 流程，这在大多数组织中仍主要依靠人工完成，通常需要数周时间，并且根据一些估计，每年可能花费大型公司数千万美元。

Using ORCHESTRATE MLR, teams can automatically identify, extract and manage claims in minutes, avoiding the need to comb through hundreds of marketing materials and cross-reference them with regulatory claims information.

使用ORCHESTRATE MLR，团队可以在几分钟内自动识别、提取和管理声明，避免了需要梳理数百份营销材料并将它们与监管声明信息进行交叉引用的麻烦。

According to EVERSANA – which is pharmaphorum's parent company – annotation and cross-referencing for creative-type documents against claims data can now be completed in just a few clicks.

根据 EVERSANA（pharmaphorum 的母公司）的说法，现在只需点击几下即可完成针对索赔数据的创意型文档的注释和交叉引用。

Users of the system will see all claims identified in the document and what needs to be updated and can make these updates in real-time, resulting in 90% faster content updates and an overall reduction in content reviews by as much as 50%, according to a statement on the launch.

根据发布会上的一份声明，系统用户将看到文档中识别的所有声明以及需要更新的内容，并能够实时进行这些更新，从而使内容更新速度提高 90%，内容审查总体减少多达 50%。

Testing in partnership with several life sciences companies has suggested it can reduce submission errors by 86% and result in cost savings of around 35% for a typical MLR team.

与多家生命科学公司合作进行的测试表明，它可以将提交错误减少86%，并为典型的MLR团队节省约35%的成本。

EVERSANA chief executive Jim Lang said ORCHESTRATE MLR is a 'game changer' for life sciences companies and will 'set a new standard for efficiency, compliance, and quality that is much needed in today's industry.'

EVERSANA首席执行官吉姆·朗表示，ORCHESTRATE MLR对生命科学公司而言是“游戏规则的改变者”，将“为当今行业亟需的效率、合规性和质量设定新标准。”

The software is built on Amazon Bedrock suite of generative AI (GenAI) foundation models and was created by EVERSANA in collaboration with Amazon Web Services (AWS), product engineering specialist Modus Create, and

该软件基于亚马逊Bedrock系列生成式人工智能（GenAI）基础模型构建，由EVERSANA与亚马逊网络服务（AWS）、产品工程专家Modus Create以及共同创建。

Veeva

Veeva

, a specialist in cloud software for the life sciences industry.

，一家专注于生命科学行业的云软件专家。

'Generative AI is transforming the life sciences industry by accelerating R&D, improving efficiency in manufacturing, and streamlining the path to commercialisation,' said Dan Sheeran, AWS' general manager, healthcare and life sciences.

“生成式人工智能正在通过加速研发、提高制造效率以及简化商业化路径来变革生命科学行业，”AWS医疗保健和生命科学总经理丹·谢兰表示。

'The AI moment for life sciences is happening now, and our collaboration with EVERSANA demonstrates how AI technology is delivering solutions that not only solve long-standing industry challenges but also bring better therapies to patients faster.'

“生命科学领域的人工智能时代正在到来，我们与EVERSANA的合作展示了人工智能技术如何提供解决方案，不仅解决了行业长期存在的挑战，还加速了为患者带来更好的治疗方案。”